BeyondSpring announces initiation of phase 3 clinical development for Plinabulin for CIN
BeyondSpring announced the Company has initiated the Phase 3 portion of Study 105 evaluating its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia associated with docetaxel, a cytotoxic chemotherapeutic. CIN is a common side effect of many cancer chemotherapies. March 19, 2018